# C_2006258EN.01002501.xml

| 26.10.2006 | EN | Official Journal of the European Union | C 258/25 |
| --- | --- | --- | --- |

26.10.2006

EN

Official Journal of the European Union

C 258/25

---

Prior notification of a concentration

(Case COMP/M.4314 — Johnson & Johnson/Pfizer Consumer Healthcare)

(2006/C 258/08)

(Text with EEA relevance)

| 1. | On 19 October 2006, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Johnson & Johnson (‘J&J’, USA), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of part of the undertaking Pfizer Inc. (‘Pfizer’, USA), namely Pfizer's entire consumer healthcare division, Pfizer Consumer Health Care (‘PCH’, USA), by way of purchase of shares and assets. |
| --- | --- |

1.

On 19 October 2006, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Johnson & Johnson (‘J&J’, USA), acquires within the meaning of Article 3(1)(b) of the Council Regulation control of part of the undertaking Pfizer Inc. (‘Pfizer’, USA), namely Pfizer's entire consumer healthcare division, Pfizer Consumer Health Care (‘PCH’, USA), by way of purchase of shares and assets.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Johnson & Johnson: consumer care products, pharmaceuticals, medical devices and diagnostics; |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Johnson & Johnson: consumer care products, pharmaceuticals, medical devices and diagnostics;

| — | for Pfizer Consumer Healthcare: personal care and over-the-counter pharmaceutical products. |
| --- | --- |

—

for Pfizer Consumer Healthcare: personal care and over-the-counter pharmaceutical products.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4314 — Johnson & Johnson/Pfizer Consumer Healthcare, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4314 — Johnson & Johnson/Pfizer Consumer Healthcare, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

B-1049 Bruxelles/Brussel

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---